Optimal designs for phase II/III drug development programs including methods for discounting of phase II results.

导出 OA

翻译打印收藏纠错

作者： Stella,Erdmann ^[1] ; Marietta,Kirchner ^[2] ; Heiko,Götte ^[3] ; Meinhard,Kieser ^[2]

作者单位： Institute of Medical Biometry and Informatics, University of Heidelberg, Im Neuenheimer Feld 130.3, D-69120, Heidelberg, Germany. erdmann@imbi.uni-heidelberg.de. ^[1] Institute of Medical Biometry and Informatics, University of Heidelberg, Im Neuenheimer Feld 130.3, D-69120, Heidelberg, Germany. ^[2] Merck Healthcare KGaA, Frankfurter Str. 250, D-64293, Darmstadt, Germany. ^[3]

关键词 Assurance Bias adjustment Drug development program Optimization Probability of success Sample size Software

主题词贝叶斯定理(Bayes Theorem);人类(Humans);概率(Probability);研究设计(Research Design);样本大小(Sample Size)

DOI 10.1186/s12874-020-01093-w

PMID 33036572

发布时间 2022-05-31

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交